Relmada Therapeutics Stock Price on December 2, 2024
| RLMD Stock | USD 3.29 0.27 8.94% |
Below is the normalized historical share price chart for Relmada Therapeutics extending back to June 20, 2014. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Relmada Therapeutics stands at 3.29, as last reported on the 3rd of December, with the highest price reaching 3.40 and the lowest price hitting 2.90 during the day.
If you're considering investing in Relmada Stock, it is important to understand the factors that can impact its price. Relmada Therapeutics appears to be moderately volatile, given 3 months investment horizon. Relmada Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.12, which implies the firm had a 0.12% return per unit of risk over the last 3 months. We have found thirty technical indicators for Relmada Therapeutics, which you can use to evaluate the volatility of the company. Please evaluate Relmada Therapeutics' Risk Adjusted Performance of 0.0846, semi deviation of 2.59, and Coefficient Of Variation of 999.41 to confirm if our risk estimates are consistent with your expectations.
At present, Relmada Therapeutics' Other Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation is expected to grow to about 46 M, whereas Common Stock Total Equity is forecasted to decline to about 25.7 K. . The current year's Price Earnings To Growth Ratio is expected to grow to 0.03, whereas Price To Sales Ratio is forecasted to decline to 8,752. Relmada Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 9th of October 2014 | 200 Day MA 3.7239 | 50 Day MA 3.3167 | Beta 0.415 |
Relmada |
Sharpe Ratio = 0.1177
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RLMD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.04 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.48 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Relmada Therapeutics is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Relmada Therapeutics by adding it to a well-diversified portfolio.
Price Book 2.0845 | Book Value 2.836 | Enterprise Value 45.2 M | Enterprise Value Ebitda 0.5431 | Shares Float 27.5 M |
Related Headline
Cytokinetics Headline on 2nd of December 2024
Disposition of 5000 shares by Robert Blum of Cytokinetics at... by MacroaxisInsider
Filed transaction by Cytokinetics Director, Officer: President & Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Relmada Therapeutics Valuation on December 2, 2024
It is possible to determine the worth of Relmada Therapeutics on a given historical date. On December 2, 2024 Relmada was worth 2.99 at the beginning of the trading date compared to the closed value of 3.29. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Relmada Therapeutics stock. Still, in general, we apply an absolute valuation method to find Relmada Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Relmada Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Relmada Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 2.89 | 3.07 | 2.78 | 3.02 | 111,990 | |
12/02/2024 | 2.99 | 3.40 | 2.90 | 3.29 | 262,940 |
| 2.99 | 3.40 | 2.90 | 3.29 | 0.00 |
| Backtest Relmada Therapeutics | | | Relmada Therapeutics History | | | Relmada Therapeutics Valuation | Previous | Next |
Relmada Therapeutics Trading Date Momentum on December 2, 2024
| On December 03 2024 Relmada Therapeutics was traded for 3.29 at the closing time. The top price for the day was 3.40 and the lowest listed price was 2.90 . There was no trading activity during the period 0.0. Lack of trading volume on December 3, 2024 did not cause price change. The trading delta at closing time against the current closing price is 9.12% . |
Relmada Therapeutics Fundamentals Correlations and Trends
By evaluating Relmada Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Relmada Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Relmada financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Relmada Therapeutics Stock history
Relmada Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Relmada is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Relmada Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Relmada Therapeutics stock prices may prove useful in developing a viable investing in Relmada Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 30.1 M | 31.6 M | |
| Net Loss | -141.3 M | -148.4 M |
Relmada Therapeutics Quarterly Net Working Capital |
|
Relmada Therapeutics Stock Technical Analysis
Relmada Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Relmada Therapeutics Period Price Range
Low | December 3, 2024
| High |
0.00 | 0.00 |
Relmada Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Relmada Therapeutics December 3, 2024 Market Strength
Market strength indicators help investors to evaluate how Relmada Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Relmada Therapeutics shares will generate the highest return on investment. By undertsting and applying Relmada Therapeutics stock market strength indicators, traders can identify Relmada Therapeutics entry and exit signals to maximize returns
Relmada Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Relmada Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Relmada Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Relmada to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0846 | |||
| Jensen Alpha | 0.3081 | |||
| Total Risk Alpha | (0.22) | |||
| Sortino Ratio | 0.1006 | |||
| Treynor Ratio | 0.4756 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Relmada Stock analysis
When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |